Could this enzyme help remove 'zombie' cells from our tissues?
medicalxpress - Our population is aging. The United Nations reports that by 2050, the number of people age 85 and older on our planet is set to triple. But a longer life span isn't the same as a longer health span (the number of years we spend healthy). Salk Institute sc…
AI Summary: Researchers identified an enzyme that selectively targets senescent “zombie” cells, restoring tissue function in preclinical models and hinting at anti‑aging and therapeutic possibilities. The findings generated excitement for potential disease‑modifying strategies, but experts caution that translating enzyme‑based fixes from mice to humans will require careful safety studies and sober expectations.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
Christina Jewett and Dana G. Smith / nytimes - Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.
AI Summary: Federal regulators have zeroed in on a set of peptide injections gaining traction among wellness influencers and endorsed by RFK Jr., prompting internal debates about safety, evidence and regulation. FDA scientists are reviewing the products' claims and potential risks, setting up a clash between celebrity-driven demand and the agency’s evidence-based caution.
- Advisory panel votes to expand compounding despite safety warnings (4)
- FDA review and RFK Jr. clash over influencer‑favored peptides (4)
- Market hype and regulation: guidances, reporting and uncertainty (5)
Advisory panel votes to expand compounding despite safety warnings
FDA review and RFK Jr. clash over influencer‑favored peptides
Market hype and regulation: guidances, reporting and uncertainty
Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment
discovermagazine - Learn how personalized genetic therapy helped researchers treat two children with a rare form of epilepsy, enabling one to walk independently for the first time.
AI Summary: Two children with a rare, treatment‑resistant epilepsy mutation showed marked clinical improvement after receiving individualized genetic therapies—one via an antisense oligonucleotide tailored to the mutation. The cases underscore the promise of bespoke molecular medicines for devastating pediatric neurological disorders and hint that precision medicine can be both life‑changing and, yes, kind of miraculous.
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
fiercehealthcare - Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
AI Summary: Tempus is acquiring cancer-genomics company Personalis for roughly $1.5 billion to expand its testing and genomic-service footprint, betting bigger on integrated sequencing and AI-driven oncology diagnostics. The move accelerates Tempus’s push to scale tumor profiling and clinical assays nationwide — and yes, expect louder claims about “transforming cancer care.”
How we are engineering bacteria to eat cancer
medicalxpress - Modern medicine has made significant advances in cancer treatments over the decades. But all cancer therapies still face one critical challenge: how to target cancers without damaging healthy cells.
AI Summary: Researchers engineered bacteria that selectively attack and consume tumor tissue in preclinical models, demonstrating promising tumor control and a novel mechanism to deliver anti‑cancer effects. Significant questions remain about safety, immune responses and delivery in humans, so while the “bacteria that eat cancer” headline is delightful, translation to patients will require cautious, rigorous steps.
Researchers identify immune cell that builds cancer-fighting hubs inside tumors
medicalxpress - Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity. This discovery could lead to …
AI Summary: Researchers discovered a subset of dendritic cells that orchestrate formation and maintenance of tertiary lymphoid structures—local immune “hubs”—inside tumours. These niches concentrate and sustain anti-tumour T cells, explaining how some cancers spontaneously marshal immune responses and opening avenues to boost immunotherapy by enhancing or mimicking this dendritic cell-driven architecture.
- Discovery: dendritic cells build tumour immune hubs (3)
- Molecular and systemic regulators of tumour immune hubs (3)
- Therapeutic strategies: boosting T cells and DC vaccines (3)
Discovery: dendritic cells build tumour immune hubs
Molecular and systemic regulators of tumour immune hubs
Therapeutic strategies: boosting T cells and DC vaccines
Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
New study sheds light on how Epstein-Barr virus may contribute to multiple sclerosis
medicalxpress - Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the central nervous system. For years, Epstein-Barr virus (EBV) has been strongly linked to MS, as nearly every person diagnosed with the condition shows evidence of past EBV infection.…
AI Summary: Researchers report that immune responses to Epstein‑Barr virus are implicated in multiple sclerosis, with EBV‑reactive CD4+ T cells enriched in people with MS. The work provides mechanistic evidence connecting prior infection to neuroinflammation and suggests antiviral or immune‑directed strategies might be viable prevention or treatment avenues — assuming we like attacking tiny viral culprits.
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Genetic study redefines a form of excessive sweating as a treatable neurological condition
medicalxpress - An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered a major genetic cause of hyperhidrosis (chronic and excessive sweating). The study, published in Science Advances, provides strong evidence that a genetica…
AI Summary: New research identifies a genetic basis and a tiny electrically gated ion channel in nerve cells as drivers of a form of excessive sweating, recasting it as a neurological condition rather than a benign nuisance. Findings point to potential targeted therapies that address the underlying neural mechanism rather than symptom management alone.
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
Kathleen Medora / aacr - A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses PHILADELPHIA – A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who…
AI Summary: An experimental KRAS-targeting vaccine administered to people at high risk for pancreatic cancer proved safe and generated durable immune responses, suggesting a credible path toward interception of pancreatic ductal adenocarcinoma before it takes hold. Researchers report sustained antibody and/or T-cell activity, supporting further development and larger efficacy trials.
- Broader KRAS-targeting research and technological advances (3)
- Expert and community reactions to KRAS vaccine results (3)
- Phase I KRAS vaccine: safety and durable immune responses (3)
Broader KRAS-targeting research and technological advances
Expert and community reactions to KRAS vaccine results
Phase I KRAS vaccine: safety and durable immune responses
FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
abcnews - The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol
AI Summary: The FDA approved a first‑of‑its‑kind oral cholesterol medication intended to lower LDL in high‑risk patients, offering a cheaper, pill‑based alternative to costly PCSK9 injections. Regulators cleared the treatment after reviewing trial data showing substantial LDL reductions, positioning it as a potentially more accessible option for long‑term cardiovascular risk management.
Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early
medicalxpress - A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive im…
AI Summary: Researchers validated a blood‑based test that flags individuals at elevated risk of developing Alzheimer’s symptoms up to a decade earlier, showing strong predictive accuracy across cohorts. The finding could enable earlier monitoring and trial enrollment, but raises questions about screening protocols, follow‑up care and the psychological burden of long‑lead risk information.
- Blood biomarkers forecast Alzheimer's risk years ahead (4)
- Genetics and clearance mechanisms shaping Alzheimer's onset (3)
- Sleep, frailty and resilience as non-blood early signals (3)
Blood biomarkers forecast Alzheimer's risk years ahead
Genetics and clearance mechanisms shaping Alzheimer's onset
Sleep, frailty and resilience as non-blood early signals
2nd scan uncovers missed prostate cancer, changes care for nearly half of patients: 4 notes
Ella Jeffries / beckershospitalreview - A second scan using prostate-specific membrane antigen positron emission tomography changed treatment plans for nearly half of patients with recurrent prostate cancer whose initial scan was negative, according to research published in the July issue of Th…
AI Summary: Follow-up prostate-specific membrane antigen (PSMA) PET imaging uncovered disease missed on initial scans and altered management in nearly half of patients. Repeat imaging revealed occult or more extensive disease, prompting switches from surveillance to definitive or systemic therapies and adjustments to radiation plans. The data argue for selective reimaging when staging is uncertain.
A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.